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5-Aminoimidazole-4-carboxamide ribonucleotide
(known as ZMP) is a metabolite produced in de
novo purine biosynthesis and histidine biosynthesis,
but only utilized in the cell by a homodimeric bifunc-
tional enzyme (called ATIC) that catalyzes the last
two steps of de novo purine biosynthesis. ZMP is
known to act as an allosteric activator of the cellular
energy sensor adenosine monophosphate-activated
protein kinase (AMPK), when exogenously adminis-
tered as the corresponding cell-permeable ribonu-
cleoside. Here, we demonstrate that endogenous
ZMP, produced by the aforementioned metabolic
pathways, is also capable of activating AMPK. Using
an inhibitor of ATIC homodimerization to block
the ninth step of de novo purine biosynthesis,
we demonstrate that the subsequent increase in
endogenous ZMP activates AMPK and its down-
stream signaling pathways. We go on to illustrate
the viability of using this approach to AMPK activa-
tion as a therapeutic strategy with an in vivo mouse
model for metabolic disorders.
INTRODUCTION
AMP-activated protein kinase (AMPK) is the master regulator of
cellular energy homeostasis, monitoring and responding to
changes in the intracellular AMP/ATP ratio. AMPK signaling ex-
tends through a myriad of pathways and serves to replenish
cellular ATP levels through down-regulation of anabolic path-
ways and up-regulation of catabolic pathways (Corton et al.,
1994; Ferrer et al., 1985; Hardie, 2011a; Hardie et al., 2003;
Yeh et al., 1980). AMPK activation has been demonstrated to
inhibit the proliferation of a variety of cancer cells, resulting in
activation of p53, cell-cycle arrest, and/or apoptosis depending
on the cell line studied (Rattan et al., 2005; Sengupta et al.,
2007; Su et al., 2007; Van Den Neste et al., 2010). While there
is increasing evidence to suggest that the tumor suppressor838 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The Authfunction of AMPK is dependent on cellular and genetic context
(Liang and Mills, 2013), AMPK activation holds much potential
for the treatment of several other diseases including metabolic
disorders (Narkar et al., 2008; Zhang et al., 2009). Themetabolite
5-aminoimidazole-4-carboxamide ribonucleotide (also known as
ZMP) is an allosteric activator of AMPK that is administered to
cells as its permeable ribonucleoside analog, AICAR (Corton
et al., 1995). It should be noted that there is discrepancy in the
use of ‘‘AICAR’’ as an acronym in the literature; cell biologists
tend to refer to the ribonucleotide as ZMP and the ribonucleoside
as AICAR, whereas biochemists and chemists refer to the
ribonucleotide as AICAR. To avoid potential confusion when
referring to AICAR, we use the acronym adopted by cell biolo-
gists throughout. The AMPK-activating property of AICAR (via
elevation of cellular ZMP) has been used to demonstrate the ther-
apeutic potential for amolecular activator of AMPK, but the short
half-life of intravenously administered AICAR, and the resulting
rise in levels of blood lactic acid and uric acid, make it unsuitable
for direct use as a therapeutic agent (Goodyear, 2008; Karagou-
nis and Hawley, 2009). ZMP is also a cellular metabolite, pro-
duced in histidine biosynthesis and de novo purine biosynthesis,
but ZMP is only utilized in cells by aminoimidazole carboxamide
ribonucleotide transformylase/inosine monophosphate cyclohy-
drolase (ATIC), a bifunctional 64-kDa enzyme that catalyzes the
last two steps of de novo purine biosynthesis (Ni et al., 1991).
AMPK activation by exogenous ZMP (administered as the cell-
permeable riboside AICAR) suggests a similar function for the
endogenous metabolite, indicating the possibility of regulatory
crosstalk (via ZMP) between the de novo purine biosynthesis,
histidine biosynthesis, and AMPK pathways (Rebora et al.,
2005; Corton et al., 1994; Xiao et al., 2007, 2011).
Homodimerization of ATIC is essential for its aminoimidazole
carboxamide ribonucleotide transformylase (AICART) activity
(please note that this enzyme acts on the ribonucleotide ZMP,
not the corresponding ribonucleoside AICAR), as the active site
of this enzyme is formed at the interface of two interacting ATIC
monomers, with each molecule contributing residues (Greasley
et al., 2001). An alternative approach to AMPK activation may
therefore be envisaged, whereby an inhibitor of ATIC homodime-
rization up-regulates intracellular levels of ZMP via a metabolic
block on the ninth step of the de novo purine biosynthesis
pathway. The selective targeting of AICART with competitiveors
Figure 1. Cpd14 Activates AMPK in Cells by Increasing Intracellular AICAR Levels
(A) The chemical structure of Cpd14.
(B) MCF-7 cells treated with 250 mM Cpd14 show a time-dependent increase in ZMP levels.
(C) Analysis with a FRET-based AMPK activity sensor shows a 1.15- and 1.18-fold increase in AMPK activity of MCF-7 cells treated with 250 and 500 mMCpd14,
respectively. The maximum FRET signal is shown by treating MCF-7 cells with the glycolysis inhibitor 2-DG. ***p < 0.001.
(D) (Left) MCF-7 cells cultured in low purinemediumand treatedwith Cpd14 display a dose-dependent increase in AMPKa Thr172 phosphorylation. (Right) Cpd14
has no effect on AMPKa Thr172 phosphorylation levels in MCF-7 cells cultured in high purine medium.
(E) HCT116 cells cultured in low purine medium treated with Cpd14 show a dose-dependent increase in AMPKa Thr172 phosphorylation. Data are mean ± SEM
from three independent experiments.substrateandcofactor analogshasprovedchallengingdue to the
widespreaduseof folatesbycellular enzymes.Several antifolates
that non-specifically inhibit ATIC have been reported (Desharnais
et al., 2003; Marsilje et al., 2002, 2003), and antifolate drugs,
including methotrexate, are known to also inhibit ATIC as a sec-
ondary target (Allegra et al., 1985, 1987). Recently it has been
demonstrated that inhibition of AICART and a subsequent rise
in intracellular ZMP plays a significant role in the antitumorigenic
effects of the drug pemetrexed, which is used against non-small
cell lung cancer (Racanelli et al., 2009; Rothbart et al., 2010). The
dimerization requisite for AICART activity provides a mechanism
by which ATIC may be selectively targeted by a protein-protein
interaction inhibitor over other folate-dependent enzymes, allow-
ing the activation of AMPKvia ATIC inhibition to be further probed
and examinedwith a specific inhibitor, and form the starting point
for the development of new therapeutics. We recently reported a
small-molecule inhibitor of ATIC dimerization (Spurr et al., 2012)
that was developed from a cyclic hexapeptide identified using a
genetically encoded high-throughput screening platform (Tavas-
soli and Benkovic, 2005). The molecule, named compound 14
(Cpd14, Figure 1A) was shown to inhibit AICART by disrupting
ATIC homodimerization. Here, we demonstrate that inhibition ofChemATIC dimerization in mammalian cells with this molecule leads
to up-regulation of intracellular ZMP, which in turn leads to the
activation of AMPK. The in vivo effect of AMPK activation by
this approach is probed using an obese mouse model, in which
our compound reduces elevated blood glucose levels, improves
glucose tolerance, and reduces body mass.
RESULTS
Inhibition of ATIC Homodimerization with Cpd14
Up-regulates Intracellular ZMP, and Leads to AMPK
Activation
We began by measuring changes in the intracellular ZMP levels
in MCF-7 cells treated with 250 mMCpd14; the dose was chosen
based on our previously reported effects of this compound on
the viability of MCF-7 cells (Spurr et al., 2012). A 1.5-fold rise
in ZMP levels was observed within 2 hr of treatment, which
had risen to 3-fold after 24 hr (Figure 1B). We next probed
the effect of this rise in ZMP levels on AMPK activation by two in-
dependent methods. We first used the AMPK activity reporter
(AMPKAR), a fluorescence resonance energy transfer (FRET)-
based biosensor of AMPK activity (Tsou et al., 2011) that directlyistry & Biology 22, 838–848, July 23, 2015 ª2015 The Authors 839
probes AMPK activation; we observed a 1.15-fold increase in
the FRET signal in MCF-7 cells treated with 250 mM of Cpd14,
which increased to 1.18-fold with 500 mM of Cpd14 (Figure 1C).
We used 2-deoxyglucose (2-DG), a glucose analog that inhibits
glycolysis and induces AMPK, as a positive control, and a
1.21-fold increase in the FRET signal was observed in cells
treated with 25 mM 2-DG (Figure 1C). The observed values
were in line with those previously reported for measuring
AMPK activation with this biosensor (Tsou et al., 2011) and
show that Cpd14 is activating AMPK. To further confirm
activation of AMPK, we studied the effect of Cpd14 on the
phosphorylation of AMPKa THR172, the major regulatory event
of AMPK activation (Hawley et al., 1996; Mitchelhill et al.,
1997). MCF-7 cells were treated with 125 mM, 250 mM,
500 mM, and 1 mM Cpd14, and the levels of phosphorylated
and unphosphorylated AMPKa THR172 determined by immuno-
blot analysis. A dose-dependent increase in phosphorylation
of AMPKa THR172 was observed in cells treated with Cpd14
(Figure 1D, left), further demonstrating AMPK activation by this
molecule.
There are two cellular pathways for purine metabolism, the de
novo purine biosynthesis pathway and the salvage pathway. In
the presence of high purine levels, de novo purine biosynthesis
is inhibited (Henderson and Khoo, 1965) and the salvage
pathway activated (Murray, 1971); if the mechanism of action
of Cpd14 is on target and as predicted, Cpd14 should be inactive
under conditions where the salvage pathway is activated (as in-
hibition of ATIC dimerization by Cpd14will not lead to changes to
ZMP levels, thus eliminating its AMPK-activating property). We
therefore assessed the AMPK-activating effects of Cpd14 in
MCF-7 cells cultured in high purine cell culture medium. In line
with its proposed mechanism of action, Cpd14 did not affect
the phosphorylation status of AMPKa THR172 at doses up to
1 mM in MCF-7 cells cultured in high purine medium (Figure 1D,
right). Cpd14 also did not affect AMPK activity in cells cultured in
high glucosemedium, which inactivates AMPK (Figures S1A and
S1B). We next assessed the effect of Cpd14 on the phosphory-
lation of AMPKa THR172 in endoderm-derived HCT116 colon
carcinoma cells, chosen as they are from a distinct lineage
to the ectoderm/mesoderm-derived MCF-7 mammary gland
adenocarcinoma cells. As with MCF-7 cells, we observed a
dose-dependent increase in phosphorylation of AMPKa
THR172 in cells treated with Cpd14 (Figure 1E). Together, these
results demonstrate that Cpd14 places a metabolic block on the
ninth step of de novo purine biosynthesis by inhibiting ATIC ho-
modimerization, leading to increased intracellular ZMP levels
and AMPK activation.
Cpd14 Regulates Downstream Targets of AMPK and
Cell Viability
The effect of Cpd14 on AMPK signaling was further probed
by examining downstream AMPK targets. We first assessed
the phosphorylation state of Ser79 of acetyl-CoA carboxylase
(ACC), a direct target of activated AMPK (Munday et al., 1988),
which is inactivated by phosphorylation and frequently used as
an indicator of AMPK activity in cells (Winder and Hardie,
1996). We observed a dose-dependent increase in ACC Ser79
phosphorylation in MCF-7 cells treated with Cpd14 (Figure 2A).
A similar effect from Cpd14 was observed in HCT116 cells,840 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The Authwith a dose-dependent increase in ACC Ser79 phosphorylation
observed in cells treated with Cpd14 (Figure 2B). Given that
ACC phosphorylation is a sensitive measure of AMPK activity,
we monitored the effect of 250 mM Cpd14 on ACC Ser79 phos-
phorylation in MCF-7 cells over time. An increase in ACC Ser79
phosphorylation was visible within 2 hr of CMP14 administration
(Figure 2C), with a time-dependent increase in the intensity of
the band associated with this protein (Figure 2C). We again as-
sessed the on-target nature of the observed effect from Cpd14
using high purine cell culture medium. As observed for AMPK
phosphorylation, Cpd14 had no effect on ACC phosphorylation
under these conditions (Figure S2), indicating that the observed
effects are a result of the metabolic block placed on step 9 of
de novo purine biosynthesis and the subsequent rise in intra-
cellular ZMP.
The phosphorylation state of Ser240 and Ser244 of p70 ribo-
somal protein S6 (S6) and the phosphorylation state of Thr56
of eukaryotic elongation factor 2 (eEF2) are other commonly
used markers of AMPK activity (Rothbart et al., 2010; Vainer
et al., 2014). S6 is regulated by AMPK through the mTOR
(mammalian target of rapamycin) complex; activation of AMPK
represses mTOR activity, leading to a reduction in S6 kinase 1
activity, which in turn reduces phosphorylation of S6. An
AMPK activator would therefore be expected to cause a reduc-
tion in phosphorylation of S6. In MCF-7 cells, we observed a
dose-dependent reduction in S6 phosphorylation upon treat-
ment with Cpd14 (Figure 2D). A similar reduction in S6 phosphor-
ylation was also observed in HCT116 cells upon treatment with
Cpd14 (Figure 2E). Activated AMPK directly targets eEF2 kinase,
leading to hyperphosphorylation of eEF2; a dose-dependent
increase in eEF2 phosphorylation was observed upon treatment
of MCF-7 cells with Cpd14 (Figure 2F), in line with the AMPK-
activating property of Cpd14.
We next assessed the effect of Cpd14 on the proliferation
and viability of MCF-7 and HCT116 cells. As expected from an
AMPK activator, a dose-dependent reduction in cell numbers
was observed in both HCT116 and MCF-7 cells treated with
Cpd14, with a significant effect observed at 250 mM and higher
doses (Figure 3A). Interestingly, HCT116 cells did not show a
further significant decrease in cell numbers at doses higher
than 250 mM, while a dose-dependent decline in cell number
was observed in MCF-7 cells, with 40% reduction in cell
numbers following treatment with 1 mM Cpd14. The effect of
Cpd14 on cell proliferation and viability was further probed
via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, and a dose-dependent reduction in cell growth
was again observed in both cell lines (Figure 3B). The ratio of
the number of live cells versus total particles (arising from cell
death and apoptosis) was next assessed using a microfluidic-
based cell counter. Cpd14 at doses up to 1 mM did not cause
a significant effect on the ratio of live to dead cells (Figure 3C),
indicating that the observed reduction in proliferation with
Cpd14 is due to cytostatic rather than cytotoxic effects. We
next assessed the effect of Cpd14 on the clonogenicity of
MCF-7 cells (Figure 3D), and observed a dose-dependent reduc-
tion in colony numbers (Figure 3E). Together, these data demon-
strate that the effect of Cpd14 on cell proliferation and viability is
due to a reduction in cell division, which is consistent with AMPK
activation by Cpd14.ors
Figure 2. Cpd14 Activates AMPK Signaling in Cells
(A) MCF-7 cells treated with Cpd14 show a dose-dependent increase in ACC Ser79 phosphorylation.
(B) HCT116 cells treated with Cpd14 show a dose-dependent increase in ACC Ser79 phosphorylation.
(C) MCF-7 cells treated with 250 mM Cpd14 show a time-dependent increase in ACC Ser79 phosphorylation.
(D) MCF-7 cells treated with Cpd14 cells show a dose-dependent decrease in S6 Ser240/244 phosphorylation.
(E) HCT116 cells treated with Cpd14 show a dose-dependent decrease in S6 Ser240/244 phosphorylation.
(F) MCF-7 cells treated with Cpd14 show a dose-dependent increase in eEF2 Thr56 phosphorylation.Activation of AMPK by Cpd14 Increases Cellular Oxygen
Uptake and Reduces Lactate Levels
A key effect of AMPK activation is on cell metabolism; selective
activation of AMPKhas been proposed as a potential therapeutic
for diabetes and metabolic syndrome (Hardie, 2011a, 2011b;
Viollet et al., 2006; Zhang et al., 2009). We therefore probed the
effect of Cpd14 on the metabolism of MCF-7 cells by measuring
changes inoxygenconsumption and lactic acid levels upon treat-
ment with Cpd14. We observed a 1.4-fold increase in mean oxy-
gen consumption upon treatment with 250 mM Cpd14, from
16.3 ± 0.7 to 22.5 ± 0.6 ml O2/mg protein/hr (Figure 3F). For com-
parison, treatmentwith 500mMAICAR led toa1.2-fold increase in
oxygen consumption to 20 ± 0.8 ml O2/mg protein/hr (Figure 3F).
We next measured the effect of Cpd14 on lactic acid accumula-
tion in the culture medium of MCF-7 cells. We observed a
1.25-fold decrease in lactate levels, from 17.4 ± 1.1 to 13.8 ±
1.1 nl lactate/mg protein/hr in the culture medium of cells treated
with 250mMCpd14, andadose-dependent 1.44-fold decrease in
lactate (to 12.3 ±1.1 nl lactate/mgprotein/hr) for cells treatedwith
500 mMCpd14 (Figure 3G). For comparison, a 1.3-fold decrease
in lactate was observed in the culturemedium of cells dosedwith
500mMAICAR (to 13.4 ± 0.7 nl lactate/mgprotein/hr), while base-Chemline lactate was measured as 9.3 ± 0.3 nl lactate/mg protein/hr
(1.9-fold reduction) for cells treatedwith 20mM2-DG (Figure 3G).
The increase in intracellular oxygenconsumption anddecrease in
extracellular levels of lactic acid observed in response to treat-
mentwithCpd14are in linewith its functionasanAMPKactivator.
Cpd14 Treatment Reduces Blood Glucose Levels,
ImprovesGlucoseTolerance, andReducesBodyMass in
an Obese Mouse Model
Previous studies have shown that AMPK activation in the liver
controls glucose homeostasis through (direct and indirect) inhi-
bition of gluconeogenesis, while AMPK activation in muscle
tissue mediates the beneficial effects of exercise, such as
increased fatty acid oxidation (Fullerton et al., 2013; Viollet
et al., 2006, 2009, 2010; Zhang et al., 2009). In addition, AMPK
activation by AICAR has been demonstrated to act as an exer-
cisemimetic in sedentarymice (Narkar et al., 2008).We therefore
sought to assess the effect of Cpd14 on blood glucose and body
mass in vivo; however, we first assessed the pharmacokinetic
properties of the molecule. Cpd14 was found to have excellent
stability in mouse and human microsomes, with a half-life of
more than 3 hr in each. Cpd14 was also stable in human plasma,istry & Biology 22, 838–848, July 23, 2015 ª2015 The Authors 841
Figure 3. Cpd14 Reduces Viability, Increases Oxygen Usage, and Reduces Lactate Levels in Cells
(A) Effect of Cpd14 on cell number in MCF-7 and HCT116 cells 48 hr after treatment (n = 3, each count in duplicate).
(B) Effect of Cpd14 on cell viability in MCF-7 and HCT116 cells, measured by MTT assay 48 hr after treatment. 3% DMSO was used as a control (n = 3, each in
triplicate).
(C) Effect of Cpd14 on the ratio of living cells versus total particles in MCF-7 and HCT116 cells (n = 3, each in duplicate).
(D) Treatment with Cpd14 affects clonogenic survival of MCF-7 cells.
(E) Quantification of clonogenic assay (n = 3).
(F) Oxygen consumption of MCF-7 cells 24 hr after treatment with 500 mM AICAR or 250 mM Cpd14 (n = 5, each in triplicate).
(G) Production of lactic acid in MCF-7 cells treated with 500 mM AICAR, 250 mM Cpd14, 500 mM Cpd14, or 2 mM of the glycolysis inhibitor 2-DG (n = 3, each in
triplicate).
Data shown are mean ± SEM from three independent experiments. For all data, *p < 0.05, **p < 0.01, ***p < 0.001.with no degradation observed after 2 hr of exposure. The kinetic
solubility of the molecule was also good at 201 mM. The LogD for
the molecule was relatively low at 0.7, and, likely as a result of
this, the permeability of themolecule (measured by PAMPA) was
also low, at 1 nm/s. These data suggest that poor cell perme-
ability may be the source of the disparity between the activity
of Cpd14 in vitro (Ki of 685 nM) and its active dose in cells
(250 mM).
We next examined the effect of Cpd14 in vivo; glucose toler-
ance and body mass was measured in 15-week-old male
C57BL/6 mice fed either the standard chow diet (7% kcal fat)
or a high-fat diet (45% kcal fat). The high-fat diet resulted in842 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The Authheavier and fatter animals, which are glucose intolerant and
have elevated fasting blood glucose levels (Bruce et al., 2009).
We began by measuring the effect of a single dose of Cpd14
(intraperitoneally [i.p.], 0.05 mg/g body weight) or vehicle (saline)
on the blood glucose level of animals that were fasted overnight.
In the chow-fed group, the blood glucose level of the vehicle-
treated mice remained unchanged within error (from 6.44 ±
0.1 to 6.70 ± 0.2 mmol/l) after 3 hr, while the Cpd14-
treated group showed a 21% reduction in blood glucose (from
6.47 ± 0.2 to 5.13 ± 0.2 mmol/l) after 3 hr (Figure 4A). The blood
glucose level of the high-fat-fed group was significantly elevated
compared with that in chow-fed mice. Treating the high-fat-fedors
Figure 4. The Effect of Cpd14 on Glucose
Metabolism in C57BL/6 Mice
(A) 3-hr blood glucose levels after administration
of Cpd14 or vehicle (intraperitoneally [i.p.] at
0.05 mg/g) in chow-fed or high-fat-fed 15-week-
old C57BL/6 male mice.
(B) Baseline blood glucose level after 7 days of
Cpd14 or vehicle administration (i.p. at 0.05 mg/g)
in 15-week-old C57BL/6 male mice.
(C) (Left) Blood glucose level during 2-hr glucose
tolerance test after 7 days of Cpd14 or vehicle
administration (i.p. at 0.05 mg/g) in chow-fed or
high-fat-fed 15-week-old C57BL/6 male mice.
(Right) Area under the curve for the graph on
the left.
(D) Change in body mass over 7 days of Cpd14 or
vehicle administration (i.p. at 0.05 mg/g) in (left)
chow-fed 15-week-old C57BL/6 male mice and
(right) high-fat-fed 15-week-old C57BL/6 male
mice. Average body mass of chow-fed mice =
29.1 ± 0.2 g; average body mass of high-fat-fed
mice = 35.8 ± 2.4 g.
All data shown are mean ± SEM. For all data, *p <
0.05, **p < 0.01, ****p < 0.0001.mice with vehicle did not significantly change the blood glucose
level over 3 hr (from 12.9 ± 0.5 to 12.6 ± 0.4 mmol/l), whereas
those treated with Cpd14 showed a 42% drop in blood glucose
levels (from 14.87 ± 0.6 to 8.74 ± 0.6 mmol/l) after 3 hr
(Figure 4A).
We next probed the effect of repeated Cpd14 treatment on
baseline glucose levels and glucose handling. Mice in the
chow-fed and high-fat-fed group were given a single dose of
Cpd14 or vehicle per day, for 7 days; after this time, the baseline
fasting glucose level of each group was measured. It should be
noted that the high-fat-fed mice were kept on this diet
throughout these 7 days. Cpd14 had an insignificant effect on
fasting blood glucose levels in the chow-fed group; vehicle-
treated mice had a fasting blood glucose level of 5.50 ±
0.14 mmol/l, compared with 4.71 ± 0.06 mmol/l for those treated
with Cpd14 (Figure 4B). In contrast, seven daily doses of Cpd14
had significantly reduced fasting blood glucose in the high-
fat-fed group; vehicle-treated animals had a glucose level of
9.76 ± 0.64 mmol/l, compared with 7.58 ± 0.40 mmol/l for the
Cpd14-treated animals (Figure 4B). We next examined glucoseChemistry & Biology 22, 838–handling in these animals (treated with
73 daily doses of vehicle or Cpd14) using
a glucose tolerance test. Each group was
injected with D-glucose (2 mg/g body
weight), and their blood glucose level
monitored for the following 2 hr. Cpd14
had improved glucose clearance in the
chow-fed group, with a blood glucose
level after 2 hr of 8.06 ± 0.36 mmol/l for
the vehicle-treated group versus 6.68 ±
0.44 mmol/l in the Cpd14-treated animals
(Figure 4C, left). Cpd14 treatment resulted
in a 20% reduction in the area under curve
in the chow-fed group (Figure 4C, right). In
the high-fat-fed group, there was a muchgreater rise in blood glucose levels following glucose administra-
tion, and poor glucose clearance, indicating impaired glucose
tolerance. As before, the effects of Cpd14 were amplified in
this high-fat-fed group; we observed significantly improved
glucose clearance in the Cpd14-treated, high-fat-fed group (Fig-
ure 4C, left), with 40% difference in blood glucose level after
2 hr between the vehicle-treated (17.51 ± 0.89 mmol/l) and
Cpd14-treated group (10.76 ± 0.43 mmol/l). This corresponded
to30% reduction in the area under curve for the Cpd14-treated
group (Figure 4C, right).
We also assessed the effect of Cpd14 on the body mass of the
aforementioned animals treated with 73 daily doses of vehicle or
Cpd14. The averageweight of the chow-fedgroup (initialweight of
29.1 ± 0.2 g) had increased by 0.64 ± 0.53 g in vehicle-treated an-
imals,while it haddecreasedby0.37±0.28g in theCpd14-treated
group (Figure 4D, left). In contrast to this minor change, the
average weight of the high-fat-fed group (initial weight of 35.8 ±
2.4 g) was significantly reduced in the Cpd14-treated animals;
those treated with vehicle showed a 0.85 ± 0.67 g increase in
bodymass,whereasadaily doseofCpd14 for 7 dayshad resulted848, July 23, 2015 ª2015 The Authors 843
Figure 5. AMPK Activation by Cpd14
Inhibition of ATIC homodimerization by Cpd14
leads to an increase in endogenous ZMP, which
activates AMPK and its downstream pathways.
ETC, electron transport chain; mTOR, mammalian
target of rapamycin; PRPP, phosphoribosyl pyro-
phosphate; TCA, tricarboxylic acid.in a 1.62 ± 0.83 g reduction in body mass per animal, despite
continued consumption of the high-fat diet (Figure 4D, right).
DISCUSSION
Exogenously administered ZMP (as the cell-permeable ribonu-
cleoside AICAR) has long been known to function as an allosteric
activator of AMPK (Corton et al., 1995), serving as a valuable
research tool to allow significant insight into regulation of cellular
energetics (Hardie, 2011b). Here, we demonstrate that endoge-
nous ZMP is also capable of activating AMPK by placing a meta-
bolic block on the ninth step of de novo purine biosynthesis using
an inhibitor of ATIC homodimerization (Figure 5). ZMP is synthe-
sized in cells by two independent pathways (histidine biosyn-
thesis and de novo purine biosynthesis), but only utilized in
purine biosynthesis; previous work in yeast has demonstrated
that ZMP ismore than just ametabolite, with significant crosstalk
between these two pathways occurring through ZMP (Rebora
et al., 2005). Unlike mammalian cells, however, the yeast analog
of AMPK (SNF1) is activated by ADP rather than AMP (Mayer
et al., 2011), hence ZMP does not regulate SNF1 activity in yeast
(Pinson et al., 2009). The AMPK-activating property of ZMP in
mammalian cells is unlikely to be coincidental; this regulatory
molecule (ZMP) potentially links histidine and de novo purine
biosynthesis to AMPK signaling in cells. Further studies are
required to fully decipher this regulatory role of endogenous
ZMP in mammalian cells.
Here, we have used the perquisite of ATIC dimerization for
AICART activity to probe the effect of endogenous ZMP on844 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The AuthorsAMPK activation, but it should be noted
that any inhibitor of AICART should also
share the AMPK-activating property of
Cpd14. AICART uses 10-formyltetrahy-
drofolate as a substrate, and as a result
is targeted by many antifolates; for
example, a previous study suggests that
the principal mode of metabolic inhibition
by methotrexate in MCF-7 cells is via inhi-
bition of AICART activity (Allegra et al.,
1987). In line with our observations, Alle-
gra et al. (1987)measured a 2- to 3-fold in-
crease in the intracellular ZMP pool, but
as this work was conducted prior to the
discovery of AMPK (Carling et al., 1989),
the implications of this rise in endogenous
ZMP levels for AMPK activity could not be
explored. More recent work with peme-
trexed, an antifolate used in the treatment
of non-small cell lung carcinoma, has
further probed this possibility (Racanelliet al., 2009). The primary targets of pemetrexed are dihydrofolate
reductase, thymidylate synthase, and GAR Tfase (Shih et al.,
1997), with AICART being a secondary target. Using a series of
elegant experiments, Moran and co-workers have demonstrated
the AMPK-activating property of pemetrexed, and have deter-
mined that this effect, mediated through a rise in endogenous
ZMP arising from AICART inhibition, is a key component of the
anticancer properties of pemetrexed (Racanelli et al., 2009;
Rothbart et al., 2010). Cpd14 lacks the folate backbone of the
aforementioned molecules, instead targeting AICART activity
by inhibiting homodimerization and the formation of the active
quaternary structure (Spurr et al., 2012; Tavassoli and Benkovic,
2005). Given its unique mode of action and resulting specificity,
Cpd14 provides the possibility of directly probing the role of ZMP
and ATIC in cells.
In addition to the effects of Cpd14 on AMPK and mTOR
signaling, we also observed increased cellular oxygen consump-
tion and decreased lactic acid production. Activated AMPK can
directly phosphorylate enzymes that cause the up-regulation of
oxidative phosphorylation and increases in oxygen consumption
(Jager et al., 2007; Narkar et al., 2008). However, it has been
shown that putative activators of AMPK do not necessarily
lead to up-regulated oxidative phosphorylation. Treatment with
metformin, for example, which has previously been shown to
activate AMPK in cells (Hawley et al., 2002; Shaw et al., 2005),
opposes stimulation of oxidative phosphorylation. In contrast,
treatment with AICAR augments this pathway (Cheong et al.,
2011); our data show that Cpd14 acts in the sameway as AICAR,
in line with its proposed mechanism of action (Figure 5).
In our in vivo studies, Cpd14 treatment was found to reduce
blood glucose levels and improve glucose tolerance. This effect
of Cpd14 was significantly more prominent in mice that were
made obese and glucose intolerant by being fed a high-fat
diet. Given our observations in cells, the reduction in blood
glucose following an acute dose and the improvement in glucose
tolerance following chronic treatment ismost likely due to activa-
tion of AMPK by Cpd14. AMPK activation is known to inhibit he-
patic gluconeogenesis (Kahn et al., 2005; Ruderman et al., 2013),
increase muscle glucose uptake (Steinberg and Kemp, 2009),
and promote glucose metabolism by increasing mitochondrial
biogenesis (Steinberg and Kemp, 2009). Further studies are
needed to ascertain the mechanisms by which Cpd14 controls
glucose homeostasis in vivo, but one possible route may be
via the increased phosphorylation of ACC by Cpd14 observed
in our cell assays. This reduces ACC activity, which is a requisite
for themaintenance of glucose homeostasis (O’Neill et al., 2014).
We likewise found a marked reduction in body weights of the
obese mice following chronic (7 days) treatment with Cpd14;
these mice appeared normal throughout our study, so the
reduction in weight was not due to any malaise or change in
behavior. While an effect from Cpd14 on the appetite of these
animals cannot be ruled out, the lack of weight loss in the
Cpd14-treated chow-fed mice suggests that this is not the
case; similar effects have only previously been observed when
there is marked improvement in glucose homeostasis and
enhanced fat oxidation (Goodpaster et al., 2003). Activation of
AMPK is known to increase the expression of uncoupling protein
1 in adipose tissue and thermogenesis (Vila-Bedmar et al., 2010),
and it will interesting to determine in future studies whether there
is a reduction in adipose depots in the high-fat-fed obese mice
treated with Cpd14. Our current results suggest that there is
much potential for Cpd14 as a treatment for diabetes as, unlike
current antidiabetic drugs, this compound could improve
glucose handling as well as reduce the body weight of obese
diabetic patients.
SIGNIFICANCE
AMPK is the central sensor of cellular energy homeostasis,
whose selective activation has been a long-standing goal in
drug discovery; activation of AMPK is proposed to be of
therapeutic benefit in several disorders including cancer
and metabolic syndrome. A widely used allosteric activator
of AMPK is AICAR, a cell-permeable nucleoside that is con-
verted to the active nucleotide (ZMP) in cells. AICAR is
administered to cells at 1–5 mM levels and widely used in
the laboratory. ZMP is also a metabolite, produced by de
novo purine biosynthesis and histidine biosynthesis, but
only used by a homodimeric, bifunctional enzyme called
ATIC that catalyzes the final two steps of de novo purine
biosynthesis. We use our selective inhibitor of ATIC
homodimerization to place a metabolic block on the ninth
step of purine biosynthesis, which leads to an increase in
intracellular ZMP. We demonstrate that this increase in
endogenous ZMP activates AMPK and its downstream
signaling pathways. We go on to demonstrate the possibil-
ity of using this approach as a therapeutic strategy with a
mouse model for metabolic syndrome. Our results notChemonly demonstrate a new molecular approach to selective
AMPK activation, but also suggest that AICAR acts as a
regulatory molecule that links two biosynthetic pathways
to AMPK activity.
EXPERIMENTAL PROCEDURES
All reagents were purchased from Fisher Scientific unless otherwise stated.
2-DG and ZMP were purchased from Sigma. Cpd14 was synthesized as
previously detailed (Spurr et al., 2012). Statistical analysis was performed
using GraphPad Prism and MiniTab 16. All values are expressed as the
mean ± SEM. Values of p < 0.05 were considered statistically significant.
Western blots shown are representative images from triplicates.
Cell Culture, Cell Treatments, Transfection, and Cell Counting
All cell culture reagents were purchased from Life Technologies unless other-
wise stated. Cell lines were sourced from the American TypeCulture Collection
and not grown continually for more than 3 months. All cells were cultured at
37C in a humidified 5% CO2 atmosphere. MCF-7 cells were routinely main-
tained in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin, and HCT116 cells in McCoy’s 5A medium supplemented with
10% FBS and 1% penicillin/streptomycin. Unless otherwise stated, cells
were dosed with 250 mM Cpd14 in reduced glucose medium (10 mM or
15 mM glucose for MCF-7 and HCT116 cells, respectively), supplemented
with 10% purine-free dialyzed FBS, in 0.5% (v/v) DMSO. Cells were passaged
in reduced glucose medium prior to experiments. Transient transfection was
carried out using FuGENE HD (Promega) according to the manufacturer’s in-
structions, and experiments were carried out 24 hr after transfection. Cell
counts and live/dead cell ratios were obtained using a Moxi Z Mini automated
cell counter (Orflo).
HPLC Nucleotide Analysis
MCF-7 cells were dosed with Cpd14 as described above and harvested at
different time points. Cells were detached using warm 0.05% (w/v) trypsin/
EDTA solution, washed in PBS, and the resulting cell pellet resuspended in
ice-cold 5% (w/v) trichloroacetic acid at a density of approximately 106 cells
per 200 ml trichloroacetic acid. Cells were then briefly vortexed, held on
ice for 5 min, and debris removed by centrifugation at 2,500 rpm for 5 min.
The acid-soluble fraction was neutralized by three extractions with diethyl
ether, and the lower fraction containing the nucleotides kept between
each extraction. Concurrent nucleotide extractions were then pooled and
lyophilized. For high-performance liquid chromatography (HPLC) analyses,
samples were passed through a 0.22-mM syringe filter prior to injection into
a SUPELCOSIL LC-18-T 2503 4.6-mm reverse-phase HPLC column (Sigma).
Samples were eluted at a flow rate of 0.8 ml/min using the following ratios for
each elution buffer: 0.1 M KH2PO4 (pH 6) and 90% methanol, (1:0) first
0–15 min; (4:1) 15–17.5 min; (1:9) 17.5–23 min; (0:1) 24–34 min. Absorbance
was monitored at 254 nm. Nucleotides were detected using their absorbance
at 254 nm and comparedwith the elution position of standard solutions of ATP,
ADP, AMP, ZMP, and NAD+ (all from Sigma). The area under the peaks was
quantified by integration using Empower Pro software (Waters) and ZMP con-
centration determined by fitting peak absorbance to a standard curve gener-
ated from synthetic nucleotides. It should be noted that AMPK activation has
been observed in cells detached with trypsin (Page and Lange, 1997), and
although there is no evidence that this alters the intracellular ZMP levels, the
values quoted for intracellular ZMP levels may not directly reflect ZMP levels
prior to detachment.
AMPK Activity Fluorescence Reporter Assay
The plasmid encoding AMPKARwas used as previously described (Tsou et al.,
2011). In brief, MCF-7 cells were seeded at 7,000 cells per well in black 96-well
plates 16 hr prior to transfection of the AMPKAR construct using FuGENE HD
(Promega), followed by incubation at 37C for 24 hr. Cells expressing AMPKAR
were then dosedwith Cpd14 or 2-DG for 48 hr, followed by gentle washing and
resuspension in PBS prior to independently measuring the fluorescence of
the donor eCFP fluorophore (C; excitation 439 nm/emission 476 nm) and
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a microplate reader (Tecan Infinite M200 Pro). Analysis of the FRET signal re-
sponses to each treatment type was performed by calculating the normalized
mean (Y/C) emission ratio.
Protein Immunoblotting
Cells were washed with ice-cold PBS and harvested on ice. Cells were lysed
by incubation on ice for 15 min with radioimmunoprecipitation assay (RIPA)
buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 10% [v/v] sodium-deoxycholate,
10% [v/v] IGEPAL CA-630; Sigma) containing protease inhibitor cocktail and
PhosSTOP (Roche). Lysates were sonicated for 1 min in a sonicating water
bath and then centrifuged at 10,500 rpm for 10min at 4C. The protein concen-
tration in the supernatant was quantified by the Bradford assay. The protein
samples were divided in two, and separate gels were run for phosphorylated
and non-phosphorylated proteins. Proteins were separated on 8%–12%
SDS-polyacrylamide Bis-Tris gels under denaturing conditions, transferred
to unsupported pure nitrocellulose membrane (Amersham), and subjected to
immunoblot analysis.
Rabbit monoclonal primary antibodies raised against AMPKa (D5A2,
1:500), phospho-AMPKa (Thr172, 40H9, 1:500), ACC (C83B10, 1:500), phos-
pho-acetyl-CoA carboxylase (Ser79, D7D11, 1:500), phospho-S6 ribosomal
protein (Ser240/244, 1:5,000), and S6 ribosomal protein (1:5,000; Cell
Signaling Technology) were used for blotting. Antibodies were diluted in
Tris-buffered saline containing 5% BSA and 0.1% Tween 20, and incubated
with the membrane overnight at 4C. Horseradish peroxidase-conjugated
antirabbit immunoglobulin G antibody (NA934, 1:10,000; GE Healthcare)
was used as the secondary antibody, and monoclonal anti-b-actin-peroxi-
dase antibody (A3854, 1:50,000; Sigma) served as a loading control. Bound
immunocomplexes were detected using ECL prime western blot detection
reagent (RPN2232; GE Healthcare) and analyzed using Image Lab 4.0 com-
puter software (Bio-Rad).
Cell Viability Assays
MCF-7 cells and HCT116 cells were seeded in triplicate at 6,000 cells per well
and 10,000 cells per well, respectively, on 96-well plates 16 hr prior to dosing
with Cpd14 in 200 ml of fresh medium; final concentration of solvent DMSO in
each well was 0.5% (v/v). MTT-based cell proliferation assays were per-
formed 48 hr after dosing, as follows: MTT (Sigma) was prepared in sterile
PBS and added to cells to a final concentration of 1 mM (10% v/v). Cells
were then incubated for 4 hr at 37C until intracellular punctate purple precip-
itates were clearly visible under the microscope. An equal volume of DMSO
was then added, and the cells incubated for 10 min in the dark at room tem-
perature with agitation to dissolve the insoluble formazan particles. Absor-
bance was measured at 570 nm on a microplate reader (Tecan Infinite
M200 Pro).
Clonogenic Assays
MCF-7 cells were seeded at 800 cells per dish in 6-cm dishes 16 hr prior to
dosing with 250 mM Cpd14 for 48 hr. Cells were then gently washed in PBS
and freshmedium added, and they were incubated for up to 14 days with fresh
medium added every 48–72 hr. At the end of the experiment cells were fixed by
addition of methanol/acetic acid (3:1) for 5min, then stained by incubating with
0.5% (v/v) crystal violet solution (diluted in methanol) for 10 min, and colonies
counted.
Oxygen Consumption Assays
Extracellular oxygen consumption was measured using oxygen biosensor
96-well microplates (BD Biosciences) according to the manufacturer’s instruc-
tions. In brief, cells pre-treated for 24 hr with test compounds were seeded in
triplicate on biosensormicroplates at a cell density of 13 106 cells/ml following
equilibration of the plate at 37C for 30 min. Deionized water and freshly pre-
pared 100 mM Na2SO3 were also added to represent 20% oxygen and 0%
oxygen controls, respectively. Test compounds were reintroduced to cells
and the plate covered with an airtight seal. Fluorescence (485 nm excitation/
620 nm emission) wasmeasured every 2min for approximately 1 hr using ami-
croplate reader (BMG). At the end of the experiment cells were harvested from
the plate, lysed, and total cell protein extracted using RIPA buffer as described
above, and quantified by Bradford assay. Oxygen consumption over the 1-hr
test periodwas calculated from the slope of the graph produced and standard-846 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The Authized to the 0% and 20% oxygen controls, before being normalized to the
amount of protein present in each sample.
Lactate Production Assays
Lactate in culture medium was measured with the colorimetric L-Lactate
Assay Kit (Abcam) according to the manufacturer’s instructions. MCF-7 cells
were seeded at 400,000 cells per 25-cm2 flask, 16 hr prior to dosing with
250 and 500 mM Cpd14, 500 mM AICAR, or 20 mM 2-DG for 24 hr. Cells
were then washed in PBS and fresh medium added. Medium samples (repre-
senting less than 2% of the total volume) were then collected at different time
points, filtered through a 10-kDamolecular weight cutoff centrifugal filter (Milli-
pore) to remove all proteins, diluted 100-fold, and added at 50 ml/well to a 96-
well plate, along with 50 ml/well of reaction mix. Samples were incubated at
room temperature for 30min and absorbancemeasured at 450 nm on amicro-
plate reader (Tecan Infinite M200 Pro). At the end of the experiment cells were
lysed and total protein extracted as described above, and quantified by Brad-
ford assay.
In Vivo Studies
All experiments were carried out in accordance with the UK Animals (Scientific
Procedures) Act 1986. Male C57/BL6J mice were used in the study and were
maintained under a 12-hr light/dark cycle (lights on at 07:00), and at a constant
temperature of 22C± 2Cwith food andwater available ad libitum. At 4weeks
of age the mice were randomly allocated to one of two diets: standard chow
(C; 7% kcal fat, 18% kcal protein, 75% kcal carbohydrate; Special Dietary
Services UK), or a high-fat diet (45% kcal fat, 20% kcal protein, 35% kcal car-
bohydrate; Special Dietary Services UK). In one study, mice from both dietary
groups were fasted overnight at 15 weeks of age. Fasting glucose concentra-
tion was measured from whole blood obtained from the tail vein before the
mice were injected i.p. with either Cpd14 (dissolved in 0.9% saline [w/v]) at a
dose of 0.05 mg/g mouse body weight or the vehicle (physiological saline).
Blood glucose concentration was then assayed using an Aviva Accu-Chek
glucometer (Roche Diagnostics Ltd UK) at 15, 30, 60, 90, 120, 150, and
180 min post i.p. injection. In another study, 15-week-old mice were given a
daily i.p. injection of Cpd14 or vehicle for 7 days. The body weights of the
mice were measured daily during this period. After 7 days of treatment, mice
were fasted overnight and injected i.p. with D-glucose (2 g/kg mouse body
weight) for a 2-hr glucose tolerance test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.chembiol.2015.06.008. In accor-
dance with Research Councils UK’s data sharing policy, the raw data from
the above experiments is available from the University of Southampton data
repository.
AUTHOR CONTRIBUTIONS
A.T. conceived, designed, and supervised the project. D.J.A. conducted all
cell-based experiments and assays. F.C. synthesized Cpd14. M.B. conducted
the nucleotide quantification assay. F.D.H. designed and supervised the oxy-
gen consumption assay. F.R.C. designed and conducted the in vivo experi-
ments. A.T. wrote the manuscript with input from all authors.
ACKNOWLEDGMENTS
The authors thank Dr. Andy Merritt and Dr. Mike J. Waring for assistance with
the pharmacokinetic studies, and Prof. Lewis C. Cantley for the plasmid en-
coding AMPKAR. We also thank the Engineering and Physical Sciences
Research Council (EP/H04986X/1 to A.T.), Cancer Research UK (A10263 to
A.T.), Medical Research Council (G0701153 to F.D.H.), and Diabetes UK (11/
0004377 to F.R.C.) for funding this work.
Received: January 19, 2015
Revised: May 28, 2015
Accepted: June 2, 2015
Published: July 2, 2015ors
REFERENCES
Allegra, C.J., Drake, J.C., Jolivet, J., and Chabner, B.A. (1985). Inhibition of
phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate
and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA 82, 4881–
4885.
Allegra, C.J., Hoang, K., Yeh, G.C., Drake, J.C., and Baram, J. (1987).
Evidence for direct inhibition of de novo purine synthesis in human MCF-7
breast cells as a principal mode of metabolic inhibition by methotrexate.
J. Biol. Chem. 262, 13520–13526.
Bruce, K.D., Cagampang, F.R., Argenton, M., Zhang, J., Ethirajan, P.L.,
Burdge, G.C., Bateman, A.C., Clough, G.F., Poston, L., Hanson, M.A., et al.
(2009). Maternal high-fat feeding primes steatohepatitis in adult mice
offspring, involving mitochondrial dysfunction and altered lipogenesis gene
expression. Hepatology 50, 1796–1808.
Carling, D., Clarke, P.R., Zammit, V.A., and Hardie, D.G. (1989). Purification
and characterization of the AMP-activated protein kinase. Copurification of
acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reduc-
tase kinase activities. Eur. J. Biochem. 186, 129–136.
Cheong, J.H., Park, E.S., Liang, J., Dennison, J.B., Tsavachidou, D., Nguyen-
Charles, C., Wa Cheng, K., Hall, H., Zhang, D., Lu, Y., et al. (2011). Dual inhi-
bition of tumor energy pathway by 2-deoxyglucose and metformin is effective
against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10,
2350–2362.
Corton, J.M., Gillespie, J.G., and Hardie, D.G. (1994). Role of the AMP-acti-
vated protein kinase in the cellular stress response. Curr. Biol. 4, 315–324.
Corton, J.M., Gillespie, J.G., Hawley, S.A., and Hardie, D.G. (1995). 5-amino-
imidazole-4-carboxamide ribonucleoside. A specific method for activating
AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565.
Desharnais, J., Hwang, I., Zhang, Y., Tavassoli, A., Baboval, J., Benkovic, S.J.,
Wilson, I.A., and Boger, D.L. (2003). Design, synthesis and biological evalua-
tion of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR
Tfase and the de novo purine biosynthetic pathway. Bioorg. Med. Chem. 11,
4511–4521.
Ferrer, A., Caelles, C., Massot, N., and Hegardt, F.G. (1985). Activation of
rat liver cytosolic 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase
by adenosine 50-monophosphate. Biochem. Biophys. Res. Commun. 132,
497–504.
Fullerton, M.D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen,
Z.P., O’Neill, H.M., Ford, R.J., Palanivel, R., O’Brien, M., et al. (2013). Single
phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the in-
sulin-sensitizing effects of metformin. Nat. Med. 19, 1649–1654.
Goodpaster, B.H., Katsiaras, A., and Kelley, D.E. (2003). Enhanced fat oxida-
tion through physical activity is associated with improvements in insulin sensi-
tivity in obesity. Diabetes 52, 2191–2197.
Goodyear, L.J. (2008). The exercise pill—too good to be true? N. Engl. J. Med.
359, 1842–1844.
Greasley, S.E., Horton, P., Ramcharan, J., Beardsley, G.P., Benkovic, S.J.,
and Wilson, I.A. (2001). Crystal structure of a bifunctional transformylase and
cyclohydrolase enzyme in purine biosynthesis. Nat. Struct. Biol. 8, 402–406.
Hardie, D.G. (2011a). AMP-activated protein kinase: a cellular energy sensor
with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans.
39, 1–13.
Hardie, D.G. (2011b). AMP-activated protein kinase: an energy sensor that
regulates all aspects of cell function. Genes Dev. 25, 1895–1908.
Hardie, D.G., Scott, J.W., Pan, D.A., and Hudson, E.R. (2003). Management of
cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546,
113–120.
Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., Carling, D., and
Hardie, D.G. (1996). Characterization of the AMP-activated protein kinase ki-
nase from rat liver and identification of threonine 172 as the major site at which
it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271, 27879–
27887.ChemHawley, S.A., Gadalla, A.E., Olsen, G.S., and Hardie, D.G. (2002). The antidia-
betic drug metformin activates the AMP-activated protein kinase cascade via
an adenine nucleotide-independent mechanism. Diabetes 51, 2420–2425.
Henderson, J.F., and Khoo, K.Y. (1965). On the mechanism of feedback inhi-
bition of purine biosynthesis de novo in Ehrlich ascites tumor cells in vitro.
J. Biol. Chem. 240, 3104–3109.
Jager, S., Handschin, C., St-Pierre, J., and Spiegelman, B.M. (2007). AMP-
activated protein kinase (AMPK) action in skeletal muscle via direct phosphor-
ylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 104, 12017–12022.
Kahn, B.B., Alquier, T., Carling, D., and Hardie, D.G. (2005). AMP-activated
protein kinase: ancient energy gauge provides clues to modern understanding
of metabolism. Cell Metab. 1, 15–25.
Karagounis, L.G., and Hawley, J.A. (2009). The 50 adenosine monophosphate-
activated protein kinase: regulating the ebb and flow of cellular energetics. Int.
J. Biochem. Cell Biol. 41, 2360–2363.
Liang, J., and Mills, G.B. (2013). AMPK: a contextual oncogene or tumor sup-
pressor? Cancer Res. 73, 2929–2935.
Marsilje, T.H., Labroli, M.A., Hedrick, M.P., Jin, Q., Desharnais, J., Baker, S.J.,
Gooljarsingh, L.T., Ramcharan, J., Tavassoli, A., Zhang, Y., et al. (2002). 10-
Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF):
a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and
the de novo purine biosynthetic pathway. Bioorg. Med. Chem. 10, 2739–2749.
Marsilje, T.H., Hedrick, M.P., Desharnais, J., Tavassoli, A., Zhang, Y.,
Wilson, I.A., Benkovic, S.J., and Boger, D.L. (2003). Design, synthesis,
and biological evaluation of simplified alpha-keto heterocycle, trifluoro-
methyl ketone, and formyl substituted folate analogues as potential inhibi-
tors of GAR transformylase and AICAR transformylase. Bioorg. Med. Chem.
11, 4487–4501.
Mayer, F.V., Heath, R., Underwood, E., Sanders, M.J., Carmena, D.,
McCartney, R.R., Leiper, F.C., Xiao, B., Jing, C., Walker, P.A., et al. (2011).
ADP regulates SNF1, the Saccharomyces cerevisiae homolog of AMP-acti-
vated protein kinase. Cell Metab. 14, 707–714.
Mitchelhill, K.I., Michell, B.J., House, C.M., Stapleton, D., Dyck, J., Gamble, J.,
Ullrich, C., Witters, L.A., and Kemp, B.E. (1997). Posttranslational modifica-
tions of the 50-AMP-activated protein kinase beta1 subunit. J. Biol. Chem.
272, 24475–24479.
Munday, M.R., Campbell, D.G., Carling, D., and Hardie, D.G. (1988).
Identification by amino acid sequencing of three major regulatory phosphory-
lation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331–338.
Murray, A.W. (1971). The biological significance of purine salvage. Annu. Rev.
Biochem. 40, 811–826.
Narkar, V.A., Downes, M., Yu, R.T., Embler, E., Wang, Y.X., Banayo, E.,
Mihaylova, M.M., Nelson, M.C., Zou, Y., Juguilon, H., et al. (2008). AMPK
and PPARdelta agonists are exercise mimetics. Cell 134, 405–415.
Ni, L., Guan, K., Zalkin, H., and Dixon, J.E. (1991). De novo purine nucleotide
biosynthesis: cloning, sequencing and expression of a chicken PurH cDNA en-
coding 5-aminoimidazole-4-carboxamide-ribonucleotide transformylase-IMP
cyclohydrolase. Gene 106, 197–205.
O’Neill, H.M., Lally, J.S., Galic, S., Thomas, M., Azizi, P.D., Fullerton, M.D.,
Smith, B.K., Pulinilkunnil, T., Chen, Z., Samaan, M.C., et al. (2014). AMPK
phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation
and insulin sensitivity in mice. Diabetologia 57, 1693–1702.
Page, K., and Lange, Y. (1997). Cell adhesion to fibronectin regulates mem-
brane lipid biosynthesis through 50-AMP-activated protein kinase. J. Biol.
Chem. 272, 19339–19342.
Pinson, B., Vaur, S., Sagot, I., Coulpier, F., Lemoine, S., and Daignan-Fornier,
B. (2009). Metabolic intermediates selectively stimulate transcription factor
interaction and modulate phosphate and purine pathways. Genes Dev. 23,
1399–1407.
Racanelli, A.C., Rothbart, S.B., Heyer, C.L., and Moran, R.G. (2009).
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes
ZMP accumulation, AMPK activation, and mammalian target of rapamycin in-
hibition. Cancer Res. 69, 5467–5474.istry & Biology 22, 838–848, July 23, 2015 ª2015 The Authors 847
Rattan, R., Giri, S., Singh, A.K., and Singh, I. (2005). 5-Aminoimidazole-4-car-
boxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro
and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582–
39593.
Rebora, K., Laloo, B., and Daignan-Fornier, B. (2005). Revisiting purine-histi-
dine cross-pathway regulation in Saccharomyces cerevisiae: a central role
for a small molecule. Genetics 170, 61–70.
Rothbart, S.B., Racanelli, A.C., and Moran, R.G. (2010). Pemetrexed indirectly
activates the metabolic kinase AMPK in human carcinomas. Cancer Res. 70,
10299–10309.
Ruderman, N.B., Carling, D., Prentki, M., and Cacicedo, J.M. (2013). AMPK,
insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123, 2764–
2772.
Sengupta, T.K., Leclerc, G.M., Hsieh-Kinser, T.T., Leclerc, G.J., Singh, I., and
Barredo, J.C. (2007). Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-
beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia
(ALL) cells: implication for targeted therapy. Mol. Cancer 6, 46.
Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A.,
Montminy, M., and Cantley, L.C. (2005). The kinase LKB1 mediates glucose
homeostasis in liver and therapeutic effects of metformin. Science 310,
1642–1646.
Shih, C., Chen, V.J., Gossett, L.S., Gates, S.B., MacKellar, W.C., Habeck, L.L.,
Shackelford, K.A., Mendelsohn, L.G., Soose, D.J., Patel, V.F., et al. (1997).
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple
folate-requiring enzymes. Cancer Res. 57, 1116–1123.
Spurr, I.B., Birts, C.N., Cuda, F., Benkovic, S.J., Blaydes, J.P., and Tavassoli,
A. (2012). Targeting tumour proliferation with a small-molecule inhibitor of
AICAR transformylase homodimerization. Chembiochem 13, 1628–1634.
Steinberg, G.R., and Kemp, B.E. (2009). AMPK in health and disease. Physiol.
Rev. 89, 1025–1078.
Su, R.Y., Chao, Y., Chen, T.Y., Huang, D.Y., and Lin, W.W. (2007). 5-
Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-
induced cytotoxicity in colon cancer cells through AMP-activated protein kinase
signaling. Mol. Cancer Ther. 6, 1562–1571.
Tavassoli, A., and Benkovic, S.J. (2005). Genetically selected cyclic-peptide
inhibitors of AICAR transformylase homodimerization. Angew. Chem. Int. Ed.
Engl. 44, 2760–2763.
Tsou, P., Zheng, B., Hsu, C.H., Sasaki, A.T., and Cantley, L.C. (2011). A fluo-
rescent reporter of AMPK activity and cellular energy stress. Cell Metab. 13,
476–486.848 Chemistry & Biology 22, 838–848, July 23, 2015 ª2015 The AuthVainer, G.W., Saada, A., Kania-Almog, J., Amartely, A., Bar-Tana, J., and
Hertz, R. (2014). PF-4708671 activates AMPK independently of p70S6K1 inhi-
bition. PLoS One 9, e107364.
Van Den Neste, E., Van den Berghe, G., and Bontemps, F. (2010). AICA-ribo-
side (acadesine), an activator of AMP-activated protein kinase with potential
for application in hematologic malignancies. Expert Opin. Investig. Drugs 19,
571–578.
Vila-Bedmar, R., Lorenzo, M., and Fernandez-Veledo, S. (2010). Adenosine
50-monophosphate-activated protein kinase-mammalian target of rapamycin
cross talk regulates brown adipocyte differentiation. Endocrinology 151,
980–992.
Viollet, B., Foretz, M., Guigas, B., Horman, S., Dentin, R., Bertrand, L., Hue, L.,
and Andreelli, F. (2006). Activation of AMP-activated protein kinase in the liver:
a new strategy for the management of metabolic hepatic disorders. J. Physiol.
574, 41–53.
Viollet, B., Guigas, B., Leclerc, J., Hebrard, S., Lantier, L., Mounier, R.,
Andreelli, F., and Foretz, M. (2009). AMP-activated protein kinase in the regu-
lation of hepatic energy metabolism: from physiology to therapeutic perspec-
tives. Acta Physiol. (Oxf.) 196, 81–98.
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S.,
and Andreelli, F. (2010). AMPK inhibition in health and disease. Crit. Rev.
Biochem. Mol. Biol. 45, 276–295.
Winder, W.W., and Hardie, D.G. (1996). Inactivation of acetyl-CoA carboxylase
and activation of AMP-activated protein kinase in muscle during exercise. Am.
J. Physiol. 270, E299–E304.
Xiao, B., Heath, R., Saiu, P., Leiper, F.C., Leone, P., Jing, C., Walker, P.A.,
Haire, L., Eccleston, J.F., Davis, C.T., et al. (2007). Structural basis for AMP
binding to mammalian AMP-activated protein kinase. Nature 449, 496–500.
Xiao, B., Sanders, M.J., Underwood, E., Heath, R., Mayer, F.V., Carmena, D.,
Jing, C., Walker, P.A., Eccleston, J.F., Haire, L.F., et al. (2011). Structure of
mammalian AMPK and its regulation by ADP. Nature 472, 230–233.
Yeh, L.A., Lee, K.H., and Kim, K.H. (1980). Regulation of rat liver acetyl-CoA
carboxylase. Regulation of phosphorylation and inactivation of acetyl-CoA
carboxylase by the adenylate energy charge. J. Biol. Chem. 255, 2308–
2314.
Zhang, B.B., Zhou, G., and Li, C. (2009). AMPK: an emerging drug target for
diabetes and the metabolic syndrome. Cell Metab. 9, 407–416.ors
